Visit the ACCC COVID-19 Resource Center & Discussion Group for Insights on Providing Optimal Patient Care During the Pandemic.



In This Section

Home / Attend / Upcoming Webinar Details

Case Studies in IO: A Closer Look at Care Delivery in Illinois

Wed, June 19, 2019
7:00 AM to 8:30 AM (Central Daylight Time)

This educational activity is jointly provided by AXIS Medical Education and the Association of Community Cancer Centers (ACCC).

This activity is supported by an educational grant from the Bristol-Myers Squibb Company.

Target Audience

This initiative aims to provide guidance for oncologists; oncology nurse practitioners, physician assistants, nurses, and pharmacists; patient navigators, social workers, and other healthcare professionals who are involved in the care of patients with cancer in the community setting, on the practical issues related to the optimal integration of immunotherapies to treat cancer.


This program will focus on clinical evidence for optimal integration of immunotherapy agents into clinical practice. Topics covered include: monitoring for and managing immune-related adverse events, care coordination and communication between oncology and non-oncology specialists, shared decision-making, reimbursement, post-IO survivorship, and assessment of institution- or practice-specific gaps.


  • Assess alignment of current practice with best practices related to coordination and communication within the multidisciplinary cancer care team to optimize integration of cancer immunotherapies.
  • Assess current vs best practices concerning coordination and communication with the multidisciplinary cancer care team to optimize integration of cancer immunotherapies.
  • Evaluate tools and resources for monitoring and managing immune-related adverse events associated with immunotherapies in cancer.
  • Examine solutions to coverage and access barriers to offering cancer immunotherapies in the community.
  • Discuss strategies to improve active patient engagement in shared decision-making process.


7:00 – 7:05      Welcome and Introductions
7:05 – 7:20      Assessment of practice patterns for optimal integration of immunotherapies
7:20 – 8:20      Clinical Case Presentations and Discussion 
8:20 – 8:30      Program Evaluation, Post-activity assessment, and Question and Answers



Sigrun Hallmeyer, MD
Director, ALGH Oncology Service Line;
Director, ALGH Cancer Survivorship Center;
Advocate Medical Group
Division Oncology, Advocate Lutheran General Hospital


Accreditation Statement

Jointly Accredited Provider LogoIn support of improving patient care, this activity has been planned and implemented by AXIS Medical Education and Association of Community Cancer Centers (ACCC). AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


IPCE LogoThis activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

Credit Designation for Physicians

AXIS Medical Education designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation for Nursing

AXIS Medical Education designates this continuing nursing education activity for 1.5 contact hours.

Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

AXIS Contact Information

For information about the accreditation of this program please contact AXIS at

Disclosure of Conflicts of Interest

AXIS Medical Education requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

Name of Faculty or Presenter/Planner

Reported Financial Relationship

Sigrun Hallmeyer, MD


Speaker: Bristol-Meyers Squibb, Advisor/Consultant: Bristol-Meyers Squibb, Array, Cardinal Health


The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

Name of Planner/Manager/Reviewer

Reported Financial Relationship

Latha Shivakumar, PhD

Nothing to disclose

Hira Chowdhary

Nothing to disclose

Leigh M. Boehmer, PharmD, BCOP

Nothing to disclose

Marilyn Haas, PhD, RN, CNS, ANP-BC

Nothing to disclose

Dee Morgillo, MEd.,CHCP

Nothing to disclose

Linda Gracie King

Nothing to disclose

Robert Mocharnuk MD

Common stock: Merck



Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Safeguards Against Commercial Bias

AXIS Medical Education affirms that the content and format of the certified activity and its related materials promote improvements and quality in healthcare and do not promote a specific proprietary business interest of a commercial entity. To this end, AXIS employs several strategies to ensure the absence of commercial bias, including, but not limited to, review of all planned content for certified activities to ensure adherence to the Accreditation Council for Continuing Medical Education’s content validation guidelines, and resolution of any actual or perceived conflicts of interest that exist.

We employ several metrics during review of content materials, including:

  1. Fair balance
    • Recommendations must be based on a reasonable and valid interpretation of the information available on the subject matter
    • No single product or service is overrepresented when other equal, competing products or services are available for inclusion
  2. Scientific objectivity of studies mentioned in the activity or used as the basis for content development

Fee Information

There is no fee for this educational activity.

Method of Participation and Request for Credit 

To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing and returning the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be emailed to you within 3 weeks.